Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...

PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...

Public health authorities outline who needs which vaccines, organized by age and other key variables—important information ...

Rhode Island has the highest vaccination rate across the country, while Mississippi was found to have the lowest, a new study ...